Labiotech.eu

PCSK9’s second act: From antibodies to gene editing

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
FierceBiotech

Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...
Healio

Topline data show efficacy, safety of novel oral PCSK9 inhibitor for LDL lowering

Please provide your email address to receive an email when new articles are posted on . Topline results from two phase 3 trials of a novel oral PCSK9 inhibitor for treatment of HeFH and hyperlipidemia ...
FierceBiotech

AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
Hosted on MSN

First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...
Monthly Prescribing Reference

Oral PCSK9 Inhibitor Significantly Reduces LDL-C in Two Phase 3 Trials

Enlicitide decanoate statistically significantly reduced LDL-C compared with placebo (CORALreef HeFH) and vs other oral non-statin therapies (CORALreef AddOn). Topline data were announced from two ...
Hosted on MSN

MSD’s oral PCSK9 scores Phase III hat-trick

MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has succeeded in a third Phase III trial in patients with hypercholesterolemia. In the CORALreef Lipids trial (NCT05952856), ...